|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| Insulin Resistance | |||||
| 2 | More general conditions related to this trial | ||||
| Glucose Metabolism Disorders | |||||
| Hyperinsulinism | |||||
| Mental Disorders | |||||
| Metabolic Diseases | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Interventions listed in this trial | ||||
| Aripiprazole | |||||
| Placebo | |||||
| 4 | More general drug interventions related to this trial | ||||
| Antipsychotic Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||